Alto Neuroscience, Inc. (NYSE:ANRO) Receives Average Recommendation of “Moderate Buy” from Brokerages

Alto Neuroscience, Inc. (NYSE:ANRO) has earned a consensus rating of “Moderate Buy” from the seven research firms that are currently covering the company, Marketbeat Ratings reports. Three analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $15.40.

A number of equities analysts have issued reports on the stock. Wedbush reaffirmed a “neutral” rating and set a $4.00 price objective on shares of Alto Neuroscience in a report on Thursday, May 15th. HC Wainwright started coverage on Alto Neuroscience in a research note on Monday, April 7th. They issued a “buy” rating and a $10.00 price objective on the stock. Finally, William Blair restated an “outperform” rating on shares of Alto Neuroscience in a research note on Friday, March 21st.

Alto Neuroscience Stock Performance

NYSE:ANRO opened at $2.63 on Wednesday. The company has a fifty day moving average of $2.41 and a 200-day moving average of $3.25. The firm has a market capitalization of $71.06 million, a P/E ratio of -1.12 and a beta of 1.93. The company has a quick ratio of 13.09, a current ratio of 13.10 and a debt-to-equity ratio of 0.05. Alto Neuroscience has a twelve month low of $1.60 and a twelve month high of $17.55.

Alto Neuroscience (NYSE:ANRO) last posted its quarterly earnings results on Tuesday, May 13th. The company reported ($0.53) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.59) by $0.06. As a group, sell-side analysts anticipate that Alto Neuroscience will post -2.54 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Point72 Asset Management L.P. boosted its stake in Alto Neuroscience by 73.1% in the fourth quarter. Point72 Asset Management L.P. now owns 1,692,153 shares of the company’s stock worth $7,158,000 after buying an additional 714,461 shares in the last quarter. Armistice Capital LLC raised its holdings in shares of Alto Neuroscience by 146.2% during the first quarter. Armistice Capital LLC now owns 1,600,000 shares of the company’s stock valued at $3,456,000 after acquiring an additional 950,000 shares in the last quarter. Vestal Point Capital LP raised its holdings in shares of Alto Neuroscience by 40.8% during the fourth quarter. Vestal Point Capital LP now owns 915,000 shares of the company’s stock valued at $3,870,000 after acquiring an additional 265,000 shares in the last quarter. AWM Investment Company Inc. raised its holdings in Alto Neuroscience by 31.1% in the first quarter. AWM Investment Company Inc. now owns 901,984 shares of the company’s stock worth $1,948,000 after purchasing an additional 214,153 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD raised its holdings in Alto Neuroscience by 4.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 844,823 shares of the company’s stock worth $3,575,000 after purchasing an additional 36,319 shares in the last quarter.

About Alto Neuroscience

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.